Mazindol for Cocaine Abuse - 2

Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT00000277
Collaborator
National Institute on Drug Abuse (NIDA) (NIH), VA Connecticut Healthcare System (U.S. Fed)
0
1
59
0

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Mazindol for Cocaine Abuse
Study Start Date :
Sep 1, 1994
Actual Primary Completion Date :
Aug 1, 1999
Actual Study Completion Date :
Aug 1, 1999

Outcome Measures

Primary Outcome Measures

  1. Side effects []

  2. Drug use []

  3. Retention []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Please contact site for information.

Contacts and Locations

Locations

Site City State Country Postal Code
1 VA Connecticut Healthcare System New Haven Connecticut United States 06519

Sponsors and Collaborators

  • Yale University
  • National Institute on Drug Abuse (NIDA)
  • VA Connecticut Healthcare System

Investigators

  • Principal Investigator: Thomas R Kosten, M.D., VA Connecticut Healthcare System

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT00000277
Other Study ID Numbers:
  • NIDA-09250-2
  • P50DA009250
  • P50-09250-2
First Posted:
Sep 21, 1999
Last Update Posted:
Jun 18, 2020
Last Verified:
Jun 1, 2020
Keywords provided by Yale University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2020